Loading...
XSHE002019
Market cap1.71bUSD
Jan 15, Last price  
10.33CNY
1D
-1.24%
1Q
-9.86%
Jan 2017
-32.44%
Name

Yifan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002019 chart
P/E
—
P/S
3.12
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.26%
Rev. gr., 5y
-2.78%
Revenues
4.02b
+4.84%
245,057,645269,314,416346,404,621764,741,628479,922,561405,987,288379,884,873495,734,761644,191,139698,020,7731,684,984,3652,434,929,7653,504,600,9534,373,293,9784,631,795,4405,186,843,6365,400,380,5814,409,035,5853,836,640,7994,022,157,334
Net income
-551m
L
32,515,89220,480,9731,936,830240,189,33641,237,02830,369,5660014,318,69225,609,109237,909,176360,573,499704,762,7281,305,103,508737,436,708903,467,850968,390,563278,398,951127,153,950-551,073,063
CFO
349m
-26.16%
33,587,17724,123,59132,616,424248,705,17283,307,29658,612,2090029,881,967102,048,281139,735,191401,960,150855,845,8351,132,728,6031,170,900,515937,240,4201,108,506,411301,231,402472,065,141348,584,791
Dividend
Sep 25, 20240.1 CNY/sh
Earnings
May 16, 2025

Profile

Yifan Pharmaceutical Co., Ltd. produces and sells drugs and medicines in China and internationally. It provides drugs across gynecology, pediatrics, orthopedics, and dermatology therapeutic areas; therapeutic infusion solutions; and pantothenic acid and Provitamin B5 products. The company also provides Chinese traditional medicines, women's health products, and blood tumor drugs. In addition, it offers APIs, including feed additives/animal health products, skin and hair care ingredients, functional food additives, and fine chemicals; and PBAT/PBS biodegradable resins and PVB films. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is based in Hangzhou, China.
URL
https://www.yifanyy.com/
IPO date
Jul 13, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,022,157
4.84%
3,836,641
-12.98%
Cost of revenue
4,101,053
3,333,776
Unusual Expense (Income)
NOPBT
(78,896)
502,864
NOPBT Margin
13.11%
Operating Taxes
16,619
29,583
Tax Rate
5.88%
NOPAT
(95,514)
473,282
Net income
(551,073)
-533.39%
127,154
-54.33%
Dividends
(1,205)
Dividend yield
0.01%
Proceeds from repurchase of equity
(37,999)
(52,713)
BB yield
0.21%
0.34%
Debt
Debt current
594,351
1,231,239
Long-term debt
945,501
1,011,556
Deferred revenue
99,745
104,841
Other long-term liabilities
124,025
21,387
Net debt
49,437
402,326
Cash flow
Cash from operating activities
348,585
472,065
CAPEX
(504,086)
Cash from investing activities
(532,835)
Cash from financing activities
30,777
FCF
272,651
418,661
Balance
Cash
773,378
1,239,286
Long term investments
717,037
601,183
Excess cash
1,289,308
1,648,637
Stockholders' equity
5,229,672
6,162,881
Invested Capital
8,562,747
9,678,474
ROIC
5.00%
ROCE
4.38%
EV
Common stock shares outstanding
1,224,607
1,275,182
Price
14.78
20.65%
12.25
-30.48%
Market cap
18,099,689
15.87%
15,620,984
-26.76%
EV
18,128,398
16,358,069
EBITDA
191,708
731,294
EV/EBITDA
94.56
22.37
Interest
86,456
85,846
Interest/NOPBT
17.07%